Suppr超能文献

变应性鼻炎的鼻内抗组胺药和皮质类固醇:系统评价和荟萃分析。

Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.

机构信息

CINTESIS@RISE, Centre for Health Technology and Services Research, Health Research Network, Faculty of Medicine, University of Porto, Porto, Portugal; MEDCIDS, Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal.

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

出版信息

J Allergy Clin Immunol. 2024 Aug;154(2):340-354. doi: 10.1016/j.jaci.2024.04.016. Epub 2024 Apr 27.

Abstract

BACKGROUND

There is insufficient systematized evidence on the effectiveness of individual intranasal medications in allergic rhinitis (AR).

OBJECTIVES

We sought to perform a systematic review to compare the efficacy of individual intranasal corticosteroids and antihistamines against placebo in improving the nasal and ocular symptoms and the rhinoconjunctivitis-related quality of life of patients with perennial or seasonal AR.

METHODS

The investigators searched 4 electronic bibliographic databases and 3 clinical trials databases for randomized controlled trials (1) assessing adult patients with seasonal or perennial AR and (2) comparing the use of intranasal corticosteroids or antihistamines versus placebo. Assessed outcomes included the Total Nasal Symptom Score, the Total Ocular Symptom Score, and the Rhinoconjunctivitis Quality-of-Life Questionnaire. The investigators performed random-effects meta-analyses of mean differences for each medication and outcome. The investigators assessed evidence certainty using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach.

RESULTS

This review included 151 primary studies, most of which assessed patients with seasonal AR and displayed unclear or high risk of bias. Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improvements in the Total Nasal Symptom Score and Rhinoconjunctivitis Quality-of-Life Questionnaire. Azelastine-fluticasone displayed the highest probability of resulting in moderate or large improvements of Total Ocular Symptom Score. Overall, evidence certainty was considered "high" in 6 of 46 analyses, "moderate" in 23 of 46 analyses, and "low"/"very low" in 17 of 46 analyses.

CONCLUSIONS

Most intranasal medications are effective in improving rhinitis symptoms and quality of life. However, there are relevant differences in the associated evidence certainty.

摘要

背景

关于变应性鼻炎(AR)的各种鼻腔内用药的有效性,目前尚无充分的系统评价证据。

目的

我们旨在进行系统评价,比较各种鼻腔内糖皮质激素和抗组胺药与安慰剂相比,改善常年性或季节性 AR 患者的鼻部和眼部症状以及鼻结膜炎相关生活质量的疗效。

方法

研究者检索了 4 个电子文献数据库和 3 个临床试验数据库,纳入(1)评估季节性或常年性 AR 成年患者的随机对照试验,(2)比较鼻腔内糖皮质激素或抗组胺药与安慰剂的使用。评估的结局包括总鼻部症状评分、总眼部症状评分和鼻结膜炎生活质量问卷。研究者对每种药物和结局的均数差值进行了随机效应荟萃分析。研究者使用 GRADE(推荐分级的评估、制定与评价)方法评估证据质量。

结果

本综述纳入了 151 项原始研究,其中大部分评估了季节性 AR 患者,且存在不清楚或高偏倚风险。在常年性和季节性 AR 中,大多数评估的治疗均优于安慰剂。在季节性 AR 中,氮卓斯汀-糠酸氟替卡松、糠酸氟替卡松酯和丙酸氟替卡松在总鼻部症状评分和鼻结膜炎生活质量问卷方面最有可能产生中度或较大的改善。氮卓斯汀-糠酸氟替卡松在总眼部症状评分方面最有可能产生中度或较大的改善。总体而言,46 项分析中有 6 项被认为证据质量“高”,23 项为“中”,17 项为“低”/“极低”。

结论

大多数鼻腔内药物可有效改善鼻炎症状和生活质量,但相关证据质量存在显著差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验